BMGP OTC

Biomagnetics Diagnostics Corp. operates as a pioneering company at the forefront of advanced medical device development and biotechnology. The firm's diagnostic technologies prioritize the direct, real-time detection of viruses, toxins, or the disease itself. This approach differs significantly from traditional methods that rely on identifying antibodies, which are part of the body's immune response and can take several weeks to many months to manifest. The company's product portfolio features the High Throughput Screening - Magnetic Testing Platform (HTS-MTP) and the Integrity Optical Biosensor (IOBS). The HTS-MTP system is designed to provide comprehensive analysis from a single test, offering both qualitative identification of chemical elements within a substance and precise quantitative measurements of specific components. Furthermore, its optical biosensor operates on the principle of protein-receptor binding. It utilizes planar optical waveguides to bring together two or more optically tagged receptors, thereby inducing changes in fluorescence that are almost instantly recognized by tiny, integrated detectors.